Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: Outcomes from TECOS.
<h4>Objective</h4> <p>To evaluate chronic kidney disease (CKD) and cardiovascular outcomes in TECOS participants with type 2 diabetes and cardiovascular disease treated with sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i), according to baseline estimated glomerular filtra...
| Päätekijät: | , , , , , , , , , , , , , , , |
|---|---|
| Aineistotyyppi: | Journal article |
| Kieli: | English |
| Julkaistu: |
American Diabetes Association
2016
|